SG11201805109YA - Halobetasol foam composition and method of use thereof - Google Patents
Halobetasol foam composition and method of use thereofInfo
- Publication number
- SG11201805109YA SG11201805109YA SG11201805109YA SG11201805109YA SG11201805109YA SG 11201805109Y A SG11201805109Y A SG 11201805109YA SG 11201805109Y A SG11201805109Y A SG 11201805109YA SG 11201805109Y A SG11201805109Y A SG 11201805109YA SG 11201805109Y A SG11201805109Y A SG 11201805109YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- composition
- pct
- halobetasol
- suite
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/122—Foams; Dry foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 11 M1111101110101011111 HO 11111 011101011111 III 0111110111110 1111 MI International Bureau .. .... ..Yejd (10) International Publication Number (43) International Publication Date ..... .....1 WO 2017/103719 Al 22 June 2017(22.06.2017) WIPO I PCT (51) International Patent Classification: A61K 9/12 (2006.01) A61K 47/44 (2017.01) A61K 47/10 (2017.01) A61K 31/573 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (21) International Application Number: PCT/IB2016/057227 KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (22) International Filing Date: 30 November 2016 (30.11.2016) OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (25) Filing Language: English ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: 62/267,749 15 December 2015 (15.12.2015) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (71) Applicant: THERAPEUTICS INC. [US/US]; 9025 Bal- boa Avenue, Suite 100, San Diego, CA 92123 (US). TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, (72) Inventors: GAUTHIER, Robert T.; c/o Therapeutics Inc., 9025 Balboa Avenue, Suite 100, San Diego, CA 92123 (US). HAMMER, James D.; 252 Mendon Street, Uxbridge, MA 01569 (US). LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, — with international search report (Art. 21(3)) = 1-1 C:r 11 IN M © 11 IN 11 © ei (54) Title: HALOBETASOL FOAM COMPOSITION AND METHOD OF USE THEREOF C ) .,.. (57) : The present invention provides a composition and method for treating various skin diseases. The composition is for- mulated as a foamable composition and includes the corticosteroid halobetasol.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562267749P | 2015-12-15 | 2015-12-15 | |
PCT/IB2016/057227 WO2017103719A1 (en) | 2015-12-15 | 2016-11-30 | Halobetasol foam composition and method of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201805109YA true SG11201805109YA (en) | 2018-07-30 |
Family
ID=57543101
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201805109YA SG11201805109YA (en) | 2015-12-15 | 2016-11-30 | Halobetasol foam composition and method of use thereof |
Country Status (14)
Country | Link |
---|---|
US (2) | US10857159B2 (en) |
EP (1) | EP3389631B1 (en) |
JP (1) | JP2018538327A (en) |
KR (1) | KR20180098300A (en) |
CN (1) | CN108601733B (en) |
AU (1) | AU2016372789B2 (en) |
BR (1) | BR112018012349A2 (en) |
CA (1) | CA3008753C (en) |
EA (1) | EA035300B1 (en) |
ES (1) | ES2770325T3 (en) |
MX (1) | MX2018007343A (en) |
PH (1) | PH12018501278A1 (en) |
SG (1) | SG11201805109YA (en) |
WO (1) | WO2017103719A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3251657A1 (en) * | 2016-05-30 | 2017-12-06 | Sun Pharmaceutical Industries Limited | Topical aqueous spray compositions of halobetasol |
WO2018020385A1 (en) * | 2016-07-27 | 2018-02-01 | Sun Pharmaceutical Industries Limited | Touch-free topical spray of halobetasol |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9504265D0 (en) * | 1995-03-03 | 1995-04-19 | Medeva Plc | Corticosteroid-containing pharmaceutical composition |
CN1086580C (en) * | 1998-03-23 | 2002-06-26 | 阎丽 | Antipruritic ointment for dermatitis |
US6479058B1 (en) * | 1999-09-02 | 2002-11-12 | Mccadden Michael E. | Composition for the topical treatment of poison ivy and other forms of contact dermatitis |
IL152486A0 (en) * | 2002-10-25 | 2003-05-29 | Meir Eini | Alcohol-free cosmetic and pharmaceutical foam carrier |
US20060018937A1 (en) * | 2002-10-25 | 2006-01-26 | Foamix Ltd. | Steroid kit and foamable composition and uses thereof |
US7186416B2 (en) * | 2003-05-28 | 2007-03-06 | Stiefel Laboratories, Inc. | Foamable pharmaceutical compositions and methods for treating a disorder |
US20050069499A1 (en) * | 2003-09-25 | 2005-03-31 | Moshe Arkin | Foamable compositions, processes of preparing same and uses thereof |
WO2008008397A2 (en) * | 2006-07-14 | 2008-01-17 | Stiefel Research Australia Pty Ltd | Fatty acid pharmaceutical foam |
US20100202978A1 (en) * | 2009-02-12 | 2010-08-12 | Gurge Ronald M | Foamable benzoyl peroxide compositions for topical administration |
AU2010217190B2 (en) * | 2009-02-25 | 2012-10-25 | Mayne Pharma Llc | Topical foam composition |
KR20120044287A (en) * | 2009-04-24 | 2012-05-07 | 얀센 파마슈티칼즈, 인코포레이티드 | Stable topical compositions for 1,2,4-thiadiazole derivatives |
CN101926765A (en) * | 2009-06-24 | 2010-12-29 | 天津金耀集团有限公司 | Fluticasone propionate foaming agent composition |
US20110212035A1 (en) * | 2010-02-26 | 2011-09-01 | Collegium Pharmaceutical, Inc. | Emollient foams for treatment of dermatoses |
JP2014532717A (en) * | 2011-11-03 | 2014-12-08 | プレシジョン ダーマトロジー インコーポレイテッドPrecision Dermatology, Inc. | Stable skin aerosol foam with reactive propellant |
EP2804606B1 (en) * | 2012-01-19 | 2017-06-28 | Hybrid Medical, LLC | Topical therapeutic formulations |
US20140079648A1 (en) * | 2012-09-14 | 2014-03-20 | Gojo Industries, Inc. | Antimicrobial alcoholic foamable compositions |
JP6113019B2 (en) * | 2013-08-07 | 2017-04-12 | 株式会社ディスコ | Wafer division method |
EP3049063A1 (en) * | 2013-09-25 | 2016-08-03 | Sun Pharmaceutical Industries Ltd | Topical spray composition of halobetasol |
CN108601726A (en) * | 2015-12-15 | 2018-09-28 | 治疗学有限公司 | Foam compositions and preparation method thereof containing corticosteroid |
-
2016
- 2016-11-30 EA EA201891351A patent/EA035300B1/en not_active IP Right Cessation
- 2016-11-30 CA CA3008753A patent/CA3008753C/en active Active
- 2016-11-30 BR BR112018012349-8A patent/BR112018012349A2/en not_active Application Discontinuation
- 2016-11-30 SG SG11201805109YA patent/SG11201805109YA/en unknown
- 2016-11-30 AU AU2016372789A patent/AU2016372789B2/en active Active
- 2016-11-30 CN CN201680080212.2A patent/CN108601733B/en active Active
- 2016-11-30 US US15/364,966 patent/US10857159B2/en active Active
- 2016-11-30 EP EP16810067.5A patent/EP3389631B1/en active Active
- 2016-11-30 KR KR1020187020203A patent/KR20180098300A/en unknown
- 2016-11-30 MX MX2018007343A patent/MX2018007343A/en active IP Right Grant
- 2016-11-30 WO PCT/IB2016/057227 patent/WO2017103719A1/en active Application Filing
- 2016-11-30 ES ES16810067T patent/ES2770325T3/en active Active
- 2016-11-30 JP JP2018532274A patent/JP2018538327A/en active Pending
-
2018
- 2018-06-14 PH PH12018501278A patent/PH12018501278A1/en unknown
-
2019
- 2019-08-19 US US16/544,070 patent/US20190365782A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EA035300B1 (en) | 2020-05-26 |
CA3008753A1 (en) | 2017-06-22 |
EP3389631B1 (en) | 2019-11-13 |
EP3389631A1 (en) | 2018-10-24 |
AU2016372789A1 (en) | 2018-07-05 |
JP2018538327A (en) | 2018-12-27 |
US10857159B2 (en) | 2020-12-08 |
CN108601733B (en) | 2021-11-09 |
EA201891351A1 (en) | 2019-01-31 |
PH12018501278A1 (en) | 2019-01-28 |
US20190365782A1 (en) | 2019-12-05 |
BR112018012349A2 (en) | 2018-12-04 |
AU2016372789B2 (en) | 2021-12-16 |
KR20180098300A (en) | 2018-09-03 |
WO2017103719A1 (en) | 2017-06-22 |
CN108601733A (en) | 2018-09-28 |
US20170165275A1 (en) | 2017-06-15 |
CA3008753C (en) | 2023-06-20 |
ES2770325T3 (en) | 2020-07-01 |
MX2018007343A (en) | 2019-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201808990QA (en) | Compositions for topical application of compounds | |
SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
SG11201807573VA (en) | Methods for providing single-stranded rna | |
SG11201805072PA (en) | Nicotine powder delivery system | |
SG11201901138XA (en) | Facial recognition-based authentication | |
SG11201804373VA (en) | Compositions and methods for immunooncology | |
SG11201909949XA (en) | Targeted immunotolerance | |
SG11201907023UA (en) | Method of reducing neutropenia | |
SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
SG11201901438VA (en) | Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate | |
SG11201901351UA (en) | A patient interface, system and method | |
SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
SG11201408251SA (en) | A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota | |
SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
SG11201906853QA (en) | Anti-rsv monoclonal antibody formulation | |
SG11201805204WA (en) | Nicotine particle capsule | |
SG11201808525UA (en) | Anti-complement factor bb antibodies and uses thereof | |
SG11201805001UA (en) | Method of treating influenza a | |
SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same | |
SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
SG11201901517YA (en) | Wireless telecommunications methods and apparatus using system information value tag | |
SG11201808829VA (en) | Tdp-43 mitochondrial localization inhibitor for the treatment of neurodegenerative disease | |
SG11201809531SA (en) | BINDING MOLECULES SPECIFIC FOR FCγGAMMA RIIA AND USES THEREOF |